ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

GSK Gsk Plc

1,673.00
3.00 (0.18%)
30 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Gsk Plc LSE:GSK London Ordinary Share GB00BN7SWP63 ORD 31 1/4P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  3.00 0.18% 1,673.00 1,674.00 1,675.00 1,679.50 1,658.50 1,661.50 7,034,492 16:35:02
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 30.33B 4.93B 1.1970 13.99 68.96B
Gsk Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker GSK. The last closing price for Gsk was 1,670p. Over the last year, Gsk shares have traded in a share price range of 1,302.60p to 1,719.80p.

Gsk currently has 4,117,033,438 shares in issue. The market capitalisation of Gsk is £68.96 billion. Gsk has a price to earnings ratio (PE ratio) of 13.99.

Gsk Share Discussion Threads

Showing 13851 to 13873 of 33125 messages
Chat Pages: Latest  557  556  555  554  553  552  551  550  549  548  547  546  Older
DateSubjectAuthorDiscuss
22/2/2017
14:01
Apologies. I've corrected it.
bracke
22/2/2017
13:56
I told you not to mention the wor (d)!!! :)
toffeeman
22/2/2017
13:31
Toffee

Hmmm..... you may get away with it but I wouldn't discount a warning post from the anti-s brigade.

bracke
22/2/2017
13:02
Hi Bracke - yep - I know - but I didn't use the word just the start of it :)
toffeeman
22/2/2017
11:00
Toffee

You are taking a chance using the 's' word it usually brings vitriolic posts threatening all sorts of dastardly deeds.

tim

Thank you.

bracke
22/2/2017
09:40
Trying to break higher, some mini resistance around 1650p
ny boy
21/2/2017
19:25
Nice chart bracke.
tim 3
21/2/2017
18:50
I bought at 1405 and plan to keep these - but I may take out a small s at 1700 as a wee hedge.
toffeeman
21/2/2017
17:30
Well it's going up on this leg, 1715p will be difficult to get through, so could retrace to around 1645p imho but I don't really sell at resistance, just hold and add more on any retrace.
ny boy
21/2/2017
17:21
Toffee

Gold star for you. maurillac missed 'sideways'.

Worth keeping an eye on the price action if you are thinking of a, I'll say it quietly, short.

bracke
21/2/2017
16:49
Nah it may go up or down or sideways :)
toffeeman
21/2/2017
15:07
so it could go up or down, or up, down and up again ;)
m

maurillac
21/2/2017
12:46
Having reached the Median Line (middle green) it's decision time. Best option is 'zoom' through and keep going. Second best is move above ML then drop back for a successful retest. Third best is as second best but test fails to hold. Equal third, fails to break above ML and simply retraces.

I suppose I should mention the possibility that the share price simply tracks up along the ML.

GSK DAILY

bracke
21/2/2017
12:19
Courtesy of Rowan Dartington:

GlaxoSmithKline (GSK.L) Buy Income Risk 3
The Pharmaceuticals company recently announced Final results to December 2016. The results were in line with expectations with Group sales rising +17% to £27.9bn (+5% constant exchange rates), aided by a weak Sterling and growth in new products. In terms of outlook, 2017 Group EPS will depend on the timing and degree of the impact of US generic competition on Glaxo's asthma drug, Advair. Assuming a bearish case for Advair (assumes US Advair sales fall -45% to $1.36bn in 2017), core EPS will be flattish if competition begins mid-year Valuing the Group on a Dec’17 P/E of 14.5x, an 11% discount to the Market. This is good value considering that the Pharmaceutical division should not be impacted significantly by generics for several years post 2017. Total Pharmaceutical sales should be slightly higher in 2020 compared to 2016 due to new products (+£2.2bn to £6bn by 2020) outweighing the decline in US Advair sales (c £1.3bn in total). The two other divisions, Vaccines and Consumer Healthcare, should continue to trade well on the back of the Novartis acquisitions. The Group is trading at a discount to its Global Consumer Healthcare peers who trade on an average P/E of around 20x. The yield of 5% should also offer great protec-tion in these uncertain equity markets. Trump should not impact the pharmaceutical sector too much because competition has worked well in terms of the patent rules and of the strength of the Pharmacy Benefit Managers.

minerve
21/2/2017
09:00
Onwards to 1715p resistance, within a rising trend channel
ny boy
20/2/2017
00:00
No, what is it, buy/sell?
ny boy
17/2/2017
21:18
Hi there, did anybody notice the 1,351,062 trade at 16.39
somptinglad
17/2/2017
17:59
With the £ heading lower, who knows, it's possible, it's just one of a few that have been earmarked before, the low £ allows a pedestrian to make a blow out offer, therefore likely to meet approval of shareholders..interesting times ahead.
ny boy
17/2/2017
17:40
Unilever today, will glaxo be next...?
spoole5
17/2/2017
09:47
Figures, also defensive qualities when the markets correct.

Sterling’s collapse makes GlaxoSmithKline plc an attractive takeover target

ny boy
17/2/2017
09:44
17th feb Jefferies buy tp 1800p up from 1780p
philanderer
17/2/2017
07:55
Tks, I must if been thinking of another stock.
ny boy
17/2/2017
07:41
XD,Next Thursday 23th Feb 23p per share.Paid on Thursday 13th of April.
garycook
Chat Pages: Latest  557  556  555  554  553  552  551  550  549  548  547  546  Older

Your Recent History

Delayed Upgrade Clock